BGC515 / BridGene Biosci - LARVOL DELTA

BridGene Biosciences Raises $28 Million in Series B+ Financing to Accelerate Clinical Development of BGC-515 and Platform Expansion (PRNewswire) - "Proceeds from the financing will be used to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2. The funding will also support the company's second program, expected to enter the clinic in 2027..."

Financing • Solid Tumor

A Phase I Clinical Study of BGC515 Capsules in Patients With Advanced Solid Tumors (ChiCTR) - P1 | N=103 | Sponsor: Cancer Hospital of Shandong First Medical University; Suzhou BridGene Biosciences Co., Ltd.

New P1 trial • Oncology • Solid Tumor

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors (PRNewswire) - "BridGene Biosciences, Inc...announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through BridGene's cutting-edge chemoproteomic platform, IMTAC....The Phase 1 study will enroll subjects in both the US and China (NCT06452160) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGC515 as a single agent in patients with advanced solid tumors, including malignant mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with hippo pathway dysregulation."

Trial status • Mesothelioma • Oncology • Solid Tumor

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=103 | Recruiting | Sponsor: BridGene Biosciences Inc.

Metastases • New P1 trial • Mesothelioma • Oncology • Solid Tumor